Abstract | BACKGROUND: METHODS: RESULTS:
Skepinone-L and LN 950 were applicable to suppress the severity of experimental arthritis confirmed by reduced ankle swelling and histopathological analysis. Skepinone-L (3.18 ± 0.19 mm) and LN 950 (3.40 ± 0.13 mm) treatment yielded a significantly reduced ankle thickness compared to Sham-treated mice (3.62 ± 0.11 mm) on day 5 after autoantibody transfer, a time-point characterized by severe arthritis. Hypoxia imaging with [18F] FMISO revealed non-conclusive results and might not be an appropriate tool to monitor MAPK therapy in experimental RA. CONCLUSION:
|
Authors | Philipp Guenthoer, Kerstin Fuchs, Gerald Reischl, Leticia Quintanilla-Martinez, Irene Gonzalez-Menendez, Stefan Laufer, Bernd J Pichler, Manfred Kneilling |
Journal | Inflammopharmacology
(Inflammopharmacology)
Vol. 27
Issue 6
Pg. 1217-1227
(Dec 2019)
ISSN: 1568-5608 [Electronic] Switzerland |
PMID | 31037574
(Publication Type: Evaluation Study, Journal Article)
|
Chemical References |
- Dibenzocycloheptenes
- Imidazoles
- LN950
- Protein Kinase Inhibitors
- Pyridines
- skepinone-L
- fluoromisonidazole
- Misonidazole
- Mitogen-Activated Protein Kinase 10
- p38 Mitogen-Activated Protein Kinases
- Glucose-6-Phosphate Isomerase
|
Topics |
- Animals
- Arthritis, Experimental
(diagnostic imaging, drug therapy)
- Dibenzocycloheptenes
(pharmacology, therapeutic use)
- Disease Models, Animal
- Glucose-6-Phosphate Isomerase
(immunology)
- Imidazoles
(pharmacology, therapeutic use)
- Mice
- Mice, Inbred BALB C
- Misonidazole
(analogs & derivatives, pharmacokinetics)
- Mitogen-Activated Protein Kinase 10
(antagonists & inhibitors)
- Positron-Emission Tomography
- Protein Kinase Inhibitors
(therapeutic use)
- Pyridines
(pharmacology, therapeutic use)
- p38 Mitogen-Activated Protein Kinases
(antagonists & inhibitors)
|